SIREN : 435376785
SOFILORALANE is a French company founded 25 years ago, specialized in the sector Activités des sièges sociaux. Based in QUIMPERLE (29300), this company of category PME shows in 2024 a revenue of 453 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 452 732 € | 514 645 € | 355 553 € | 337 571 € | 296 352 € | 254 262 € | 231 288 € | 230 277 € | 228 778 € |
| Net income | 130 949 € | 267 257 € | 497 923 € | 11 224 € | 6 248 € | 5 233 € | 4 052 € | 10 102 € | 10 795 € |
| EBITDA | 315 227 € | 343 533 € | 232 069 € | 105 527 € | 94 804 € | 42 320 € | 16 023 € | 47 303 € | 40 974 € |
| Net margin | 28.9% | 51.9% | 140.0% | 3.3% | 2.1% | 2.1% | 1.8% | 4.4% | 4.7% |
In 2024, SOFILORALANE achieves revenue of 453 k€. Over the period 2016-2024, the company shows strong growth with a CAGR (compound annual growth rate) of +8.9%. Significant drop of -12% vs 2023. After deducting consumption (0 €), gross margin stands at 453 k€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 315 k€, representing 69.6% of revenue. Positive scissor effect: EBITDA margin improves by +2.9 pts, sign of improved operational efficiency. This high EBITDA margin provides strong self-financing capacity and resilience to uncertainties. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 131 k€, i.e. 28.9% of revenue. This profit can be retained or distributed to shareholders.
452 732 €
452 732 €
315 227 €
295 047 €
130 949 €
69.6%
The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 97%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Cash flow represents 52.0% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.
0.002%
97.018%
52.037%
0.0
47.0%
In 2024, the debt ratio of SOFILORALANE (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.
In 2024, the financial autonomy of SOFILORALANE (97.0%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
In 2024, the repayment capacity of SOFILORALANE (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.
The liquidity ratio (= Current assets / Current liabilities) stands at 1134.35. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 26.8x. Operating income very largely covers interest expenses: high safety margin.
1134.35
26.792
In 2024, the liquidity ratio of SOFILORALANE (1134.35) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
In 2024, the interest coverage of SOFILORALANE (26.8x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 85 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 59 days. The company must finance 26 days of gap between collections and payments. Overall, WCR represents 309 days of revenue, i.e. 388 k€ to permanently finance. Over 2016-2024, WCR increased by +410%, requiring additional financing.
388 267 €
85 j
59 j
0 j
309 j
Based on 103 transactions of similar company sales in 2024, the value of SOFILORALANE is estimated at 1 093 301 € (range 246 456€ - 2 085 962€). With an EBITDA of 315 227€, the sector multiple of 5.0x is applied. The price/revenue ratio is 0.38x (conservative valuation). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 103 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare SOFILORALANE with other companies in the same sector:
Voir toutes les statistiques du secteur Activités des sièges sociaux
The revenue of SOFILORALANE in 2024 is 453 k€.
Yes, SOFILORALANE generated a net profit of 131 k€ in 2024.
The headquarters of SOFILORALANE is located in QUIMPERLE (29300), in the department Finistere.
The tax return of SOFILORALANE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
SOFILORALANE operates in the sector Activités des sièges sociaux (NAF code 70.10Z). See the 'Sector positioning' section above to compare the company with its competitors.